/organisation/xoma-ltd-group-corporation-nasdaq-berkeley-california-federal-2001-7258.html
 
 
 
 
 
 

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Organisation › Details

Xoma Ltd.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(tm) (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Novartis AG) to treat neovascular (wet) age-related macular degeneration. The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and bacterial cell expression (BCE) technologies. More than 45 companies have signed BCE licenses. XOMA's development collaborators include Lexicon Genetics, Inc., Novartis, Schering-Plough Corporation and Takeda Pharmaceutical Company Limited. With a fully integrated product development infrastructure, XOMA's product development capabilities extend from preclinical sciences to product launch. *

 

Period Start 1996-04-22 existent
  Predecessor Xoma Corporation (Nasdaq: XOMA)
Product Industry pharmaceutical
     
  City n. a. Berkeley, CA
    Address record changed: 2011-05-15
     
Basic data Employees n. a.
  Currency USD
  Annual sales 67,987,000 (revenues, total, consolidated (2008) 2008-12-31)
  Profit -45,245,000 (2008-12-31)
  Cash 10,812,000 (2008-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2017-08-29

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Xoma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top